CHRONIC LYMPHOCYTIC LEUKEMIA

This study tests whether giving two pneumonia vaccines (PCV20 and PPSV23) in a series can help people with chronic lymphocytic leukemia (CLL) build a stronger immune defense against pneumococcal infections. About 61 participants with CLL, either untreated or on a specific drug, w…

This study compares a new COVID-19 booster vaccine (GEO-CM04S1) with the standard mRNA booster in 80 people with chronic lymphocytic leukemia (CLL). The new vaccine uses a modified virus to better activate T cells, which may provide stronger protection even in patients with weake…

This study tests two drugs together for people with Richter transformation, a fast-growing lymphoma that can arise from chronic lymphocytic leukemia. The drugs aim to block cancer growth and help the immune system attack the cancer. About 32 adults who have not responded to or ca…

This study tests a new drug, pirtobrutinib, against the current standard ibrutinib in people with chronic lymphocytic leukemia or small lymphocytic lymphoma. About 662 participants will be randomly assigned to one of the two oral medications to see which controls the cancer bette…

This early-stage trial tests a new gene therapy called VNX-101 for people with certain blood cancers (like leukemia and lymphoma) that have come back or not responded to standard treatments. The study aims to find the safest dose and see if the therapy can control the cancer. Abo…

This study tests whether adding venetoclax to ongoing ibrutinib or acalabrutinib treatment can eliminate remaining leukemia cells in people with high-risk chronic lymphocytic leukemia (CLL). Participants must have been on ibrutinib or acalabrutinib for at least 12 months and stil…

This study tests whether combining two targeted drugs, pirtobrutinib and venetoclax, can eliminate hard-to-treat chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) that no longer responds to standard BTK inhibitors. About 30 adults whose cancer is progressing …

This study tests a new drug, BGB-16673, against standard treatments in 150 people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) whose cancer returned or stopped responding after prior BTK inhibitor therapy. Participants will be randomly assigned to r…

This study tests whether adding the drug epcoritamab after standard treatment can clear leftover cancer cells in people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). About 22 adults who have already received at least 12 months of targeted therapy wi…

This study aims to see if carefully managing high blood pressure can prevent serious heart problems in people with certain blood cancers (like CLL or lymphoma) who are taking a type of targeted drug called a BTK inhibitor. About 100 participants will have their blood pressure clo…

This study tests a drug called glofitamab, alone or with other medicines, in people whose chronic lymphocytic leukemia has turned into a more aggressive lymphoma (Richter's transformation). About 70 adults will receive treatment to see if the cancer shrinks or disappears. The goa…

This study tests whether a faster dose increase of the drug sonrotoclax, given after initial treatment with zanubrutinib or rituximab, is safe for people with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), or mantle cell lymphoma (MCL). About 30 adults whos…

This study compares a new drug pair (sonrotoclax plus zanubrutinib) to a standard pair (venetoclax plus acalabrutinib) in 500 adults with untreated chronic lymphocytic leukemia (CLL). The goal is to see which combination better delays disease progression and clears cancer cells f…

This early-phase study tests a new drug, mosunetuzumab, alone or combined with venetoclax, in people with chronic lymphocytic leukemia (CLL) that has returned or stopped responding to other treatments. The goal is to check safety and how well the drugs work. About 137 adults with…

This study tests two different drug combinations in people with untreated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma. Participants first take acalabrutinib alone for 12 cycles, then are randomly assigned to add either venetoclax or obinutuzumab for 6 more cy…

This early-phase study tests a new immune therapy for people with advanced B-cell lymphoma or leukemia that has returned or not responded to standard treatment. Researchers take a patient's own T-cells, add a special receptor (CAR) that targets the CD19 protein on cancer cells, a…

This study is for people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who are already taking a BTKi pill (like ibrutinib). It compares staying on the BTKi pill alone versus adding a second pill, venetoclax, for one year and then stopping both. The g…

This study checks the long-term safety of the drug pirtobrutinib in people with chronic lymphocytic leukemia or non-Hodgkin lymphoma who have already completed an earlier pirtobrutinib study. Participants will continue to receive the drug or have follow-up visits. The goal is to …

This study tests a new drug, sonrotoclax, combined with an antibody therapy (obinutuzumab or rituximab) against the current standard combination (venetoclax plus rituximab) in adults with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma. About 630…

This study tests a drug called polatuzumab vedotin combined with standard chemotherapy and immunotherapy for people with Richter's transformation, a fast-growing lymphoma that can arise from chronic lymphocytic leukemia (CLL). About 20 adults will receive up to six 21-day cycles …

This study tests whether taking the targeted therapy venetoclax in cycles (on and off) works as well as taking it every day, when combined with another drug, acalabrutinib, in people with previously untreated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).…

This study tests a two-step approach to bone marrow transplant using lower doses of radiation and chemotherapy. The goal is to reduce deaths related to the transplant itself in people with various blood cancers or disorders. About 63 participants will receive this modified treatm…

This study tests a drug called APG-2575 in 75 adults with chronic lymphocytic leukemia or small lymphocytic lymphoma that has returned or stopped responding to other treatments. The goal is to see if the drug alone can shrink tumors and how safe it is. Participants take the drug …

This study tests whether adding a newer drug, epcoritamab, to a standard two-drug combination can make cancer disappear more completely and for longer in people with untreated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). About 33 adults who have not had…

This early-phase study tests a new drug called CC312 in about 44 adults with specific blood cancers (like some lymphomas and leukemias) that have returned or stopped responding to standard treatments. The main goal is to check the drug's safety and find the best dose. Researchers…

This study tests whether giving two drugs (acalabrutinib and obinutuzumab) in cycles can control chronic lymphocytic leukemia (CLL) and allow patients to stop treatment for a while. About 60 adults with untreated CLL who need therapy will participate. The goal is to see if this a…

This study compares a new oral drug, nemtabrutinib, to two standard oral drugs (ibrutinib or acalabrutinib) in people with untreated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). About 1,200 participants will be randomly assigned to receive either nemtab…

This study tests a new type of CAR T-cell therapy for adults with B-cell lymphoma or leukemia that has come back or not responded to treatment. The therapy uses specially designed immune cells to target and attack cancer cells. The goal is to find the safest dose and see how well…

This study tests a new daily pill, LP-118, in up to 100 people with blood cancers that have come back or not responded to treatment. The main goal is to find the safest dose and see how the drug works in the body. Early results will also hint at whether it can shrink tumors or sl…

This study tests an experimental pill called AS-1763 in adults with certain blood cancers (like CLL, SLL, or NHL) that have not responded to at least two prior treatments. The main goals are to find the safest dose and see how well the drug works. About 120 participants will take…

This early-stage trial tests azer-cel, a pre-made (allogeneic) CAR T cell therapy, in adults with non-Hodgkin lymphoma, B-cell acute lymphoblastic leukemia, or chronic lymphocytic leukemia that has come back or stopped responding to treatment. The goal is to check safety and see …

This study tests different schedules for starting the drug venetoclax, given with either obinutuzumab or acalabrutinib, in people with untreated chronic lymphocytic leukemia (CLL). The main goal is to find the safest way to ramp up the dose to prevent a serious side effect called…

This study looks at whether starting treatment right away with two drugs (venetoclax and obinutuzumab) is better than waiting until symptoms appear in people newly diagnosed with high-risk chronic lymphocytic leukemia or small lymphocytic lymphoma. About 247 participants will be …

This study looks at the long-term safety of the drug pirtobrutinib in adults with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have already been treated with a BTK inhibitor. Participants must have completed a prior related study and will receive pir…

This early-phase study tests a combination of three drugs (tafasitamab, acalabrutinib, and obinutuzumab) in people with previously untreated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). The goal is to check safety and see how well the drugs work togethe…

This study tests whether adding a new drug called roginolisib to two standard drugs (venetoclax and rituximab) is safe and works better for people with chronic lymphocytic leukemia (CLL) that has returned or not responded to prior treatments. About 64 adults who have already trie…

This phase 2 study tests whether adding the experimental drug emavusertib to an approved targeted therapy (zanubrutinib) can improve outcomes for adults with chronic lymphocytic leukemia (CLL) and related B-cell cancers. About 108 participants will receive the combination to see …

This early-stage study tests an experimental drug called ABBV-319 in adults with B-cell cancers (lymphomas and leukemia) that have come back or not responded to treatment. The main goals are to check safety, find the right dose, and see if the drug shrinks tumors. About 154 parti…

This study offers ongoing access to the drug ibrutinib for up to 700 people with certain blood cancers (like chronic lymphocytic leukemia or mantle cell lymphoma) who are already taking it and benefiting. The goal is to track long-term safety and see how well the drug controls th…

This study looks at the long-term safety of the drug pirtobrutinib in people with chronic lymphocytic leukemia (CLL) or non-Hodgkin lymphoma (NHL) who were already in an earlier trial. About 279 participants will continue their treatment or follow-up visits. The main goal is to t…

This study tests a combination of three drugs (zanubrutinib, obinutuzumab, and sonrotoclax) in people with previously untreated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). The main goal is to see how many participants achieve undetectable measurable re…

This study tests a one-year treatment plan using two drugs, pirtobrutinib and obinutuzumab, for people with untreated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). The goal is to see if this fixed-duration therapy can effectively control the disease. Abo…

This early-phase trial tests a new drug, SGR-1505, in about 98 adults with various B-cell blood cancers (like lymphoma or leukemia). The main goals are to check safety, find the best dose, and see how the body handles the drug. Participants must have a confirmed diagnosis and be …

This study tests whether the drug mosunetuzumab, given alone or with a BTK inhibitor (like ibrutinib), can clear tiny amounts of leftover leukemia cells in people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). About 40 adults who have already had tre…

This study tests three different doses of pirtobrutinib in about 249 people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) whose cancer came back or didn't respond after prior treatment with a BTK inhibitor. The goal is to see which dose works best an…

This study tests a combination of three drugs (acalabrutinib, venetoclax, and durvalumab) in people with Richter transformation, a rare and fast-growing lymphoma that can develop from chronic lymphocytic leukemia (CLL). The goal is to see if this treatment can help control the di…

This study tests whether adding obinutuzumab (an immunotherapy) to acalabrutinib (a targeted drug) works better than acalabrutinib alone for people with early-stage chronic lymphocytic leukemia or small lymphocytic lymphoma who are at high risk of their disease getting worse. Abo…

This study tests a new drug, BGB-16673, against an existing one, pirtobrutinib, in people with chronic lymphocytic leukemia or small lymphocytic lymphoma that has come back or not responded to prior treatment. About 500 adults will receive either drug to see which better delays c…

This study tests a new drug called BGB-16673 for people with certain B-cell blood cancers that have come back or not responded to other treatments. The drug works by breaking down a protein that helps cancer cells grow. The trial has two parts: first finding the best dose, then t…

This early-phase study tests an experimental drug called ABBV-525 in about 150 adults with B-cell blood cancers (like certain lymphomas and leukemias). The main goals are to check safety, find the best dose, and see if the drug shrinks tumors. Participants take the drug by mouth …

This study tests a combination of three drugs (venetoclax, obinutuzumab, and possibly acalabrutinib) in people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) that has come back or not responded to prior treatment. The goal is to eliminate remaining ca…

This study is testing a new drug called BGB-16673 for adults with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) whose cancer has come back or worsened after trying two other types of standard treatments. It will compare BGB-16673 against a few other treat…

This study is testing whether a combination of three drugs—pirtobrutinib, venetoclax, and obinutuzumab—can help control chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) that has come back after previous treatment. The treatment is given for a limited time, n…

This study is collecting information on a treatment for serious blood cancers like leukemia and lymphoma. Doctors use a high-dose chemotherapy and radiation regimen to wipe out a patient's diseased bone marrow, then replace it with stem cells from donated umbilical cord blood. Th…

This early-phase trial tests a vaccine (CMV-MVA Triplex) in both stem cell donors and recipients to boost immunity against cytomegalovirus (CMV) and prevent infection after a half-matched stem cell transplant. About 46 people with various blood cancers will take part. The goal is…

This study tests whether giving yearly pneumococcal vaccines to people with chronic lymphocytic leukemia (CLL) offers better protection than the current standard of revaccination every 5 years. About 80 untreated CLL patients will receive either the yearly schedule or the standar…

This study tests a vaccine (CMV-MVA Triplex) given to stem cell donors to help prevent CMV infection in patients receiving a stem cell transplant. The vaccine boosts the donor's immunity against CMV, which is then passed to the patient through the transplant. About 216 donor-reci…

This study is testing whether taking nicotinamide (a form of vitamin B3) can prevent new non-melanoma skin cancers in people who have chronic lymphocytic leukemia (CLL) and a history of these skin cancers. About 86 participants will be randomly assigned to take either nicotinamid…

This study looks at how the flu and COVID vaccines affect the immune system in people with different types of lymphoma. Researchers will measure antibody levels and immune cells over time, comparing them to people without lymphoma. The goal is to better understand how lymphoma an…

This study collects blood and tissue samples from 2,000 people—some with cancer, some without—to create a reference set for evaluating new blood tests that aim to detect multiple cancers early. Researchers will measure how accurately these tests can tell cancer patients from heal…

This study looks at how chronic lymphocytic leukemia (CLL) and a related condition called monoclonal B-cell lymphocytosis (MBL) affect bone marrow function, especially the ability to fight infections. Researchers will compare samples from 50 participants, including people with CL…

This study gathers health information from 2,000 people receiving stem cell transplants for blood cancers or immune disorders. The goal is to track survival and complications to help improve future treatments and hospital operations. No experimental therapies are given; participa…

This study analyzes whether starting treatment early for high-risk chronic lymphocytic leukemia (CLL) is worth the cost compared to waiting. Researchers will track healthcare use and quality of life in 247 Canadian patients over up to 10 years. The goal is to help doctors and hea…

This study aims to understand how chronic lymphocytic leukemia (CLL) cells use nutrients like glucose and glutamine compared to normal cells. Researchers will give participants a special tracer (a safe, labeled nutrient) and then measure how it is processed in the body. The goal …

This study tracks 50 adults with chronic lymphocytic leukemia (CLL) who are starting acalabrutinib as their only treatment. Researchers will record how long patients stay on the drug and why they stop, aiming to understand real-world effectiveness and safety. The goal is to fill …

This study is watching how people with Waldenström's macroglobulinemia, chronic lymphocytic leukemia, marginal zone lymphoma, or follicular lymphoma do on the drug zanubrutinib in everyday medical care. It will track hospital visits and quality of life, not test a new treatment. …

This study looks at genetic changes in chronic lymphocytic leukemia (CLL) patients during treatment with the drug venetoclax. Researchers want to understand how the drug affects cancer cells and the immune system. The study involves 75 adults with relapsed or refractory CLL who w…

This study aims to collect tissue samples and medical information from up to 2,750 people with chronic lymphocytic leukemia (CLL) or related conditions. Researchers will use these samples to explore the causes and biology of the disease, including new genetic markers. Participant…

This study aims to understand why some people with chronic lymphocytic leukemia (CLL) respond to a new type of drug called BTK degraders, while others do not. Researchers will collect blood, bone marrow, or lymph node samples from 60 patients over 9 years and follow them for 5 ye…

This study follows 500 people who received CAR-T cell therapy for blood cancers like leukemia, lymphoma, or multiple myeloma. Researchers will track participants for up to 15 years to see if any new cancers develop. The goal is to understand the long-term safety of this treatment…

This study measures how chronic lymphocytic leukemia (CLL) patients feel and function while taking the drug acalabrutinib in everyday life. Researchers will review medical records of 120 adults in France who started acalabrutinib for the first time. They will track quality of lif…

This study is for people starting a type of blood cancer medication called BTK inhibitors. Researchers want to see if a small heart monitor (implanted under the skin) can detect irregular heartbeats that these drugs might cause. The goal is to catch problems early and guide treat…

This study looks at whether CAR-T cell therapy reduces the protection that vaccines (like measles, mumps, and rubella) provide in people with multiple myeloma and non-Hodgkin lymphoma. Researchers will measure antibody levels before and after CAR-T treatment in 45 adults. The goa…